Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

ABN 37 06	63 259 754		
We (the entity) give ASX the following informa	ation.	
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).			
1	⁺ Class of ⁺ securities issued or to be issued	Ordinary Fully paid share (Share)	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	14,052,810	
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully-paid ordinary shares	

Name of entity

Novogen Limited ("Novogen")

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

All the shares referred to in item 2 will rank pari passu with all existing ordinary shares

5 Issue price or consideration

Issue price per Share is 0.125

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) To raise funds to fund further and ongoing research programs and to fund working capital requirements of the Company

6a Is the entity an ⁺eligible entity that has obtained security holder approval under rule 7.1A?

Yes

If Yes, complete sections 6b-6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

12 November 2014

6c Number of *securities issued without security holder approval under rule 7.1

14,052,810

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	nil	
		-	
6e	Number of *securities issued with security	N/A	
	holder approval under rule 7.3 or another		
	specific security holder approval (specify		
	date of meeting)		
	2)		
6f	Number of *securities issued under an	N/A	
01		11/A	
	exception in rule 7.2		
_	70 [†] 1 1 7 1 4		
6g	If *securities issued under rule 7.1A, was		
	issue price at least 75% of 15 day VWAP as		
	calculated under rule 7.1A.3? Include the		
	+issue date and both values. Include the		
	source of the VWAP calculation.		
6h	If *securities were issued under rule 7.1A for	N/A	
	non-cash consideration, sate date on which		
	valuation of consideration was released to		
	ASX Market Announcements		
6i	Calculate the entity's remaining issue	Under rule 7.1 -	nil
	capacity under rule 7.1 and rule 7.1A -	Under rule 7.1A	
	complete Annexure 1 and release to ASX	Officer rule 7.174	- 1111
	Market Announcements		
7	⁺ Issue dates	19 December 20	1.4
,	133de dates	1) December 20	17
	Note: The issue date may be prescribed by ASX (refer		
	to the definition of issue date in rule 19.12). For		
	example, the issue date for a pro rata entitlement issue		
	must comply with the applicable timetable in Appendix		
	7A.		
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and +class of all +securities quoted	234,514,050	Ordinary shares
O	on ASX (<i>including</i> the securities in clause 2	234,314,030	Ordinary snares
	· •		
	if applicable)		

⁺ See chapter 19 for defined terms.

Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)

Number +Class

20,859,988

Unlisted options with various exercise dates and prices

4

Unlisted convertible note with a face value of \$1,225,000

60,000,000 Unlisted convertible notes, with face values of \$1,500,000 10 Dividend policy (in the case of a trust, N/A distribution policy) on the increased capital (interests) Part 2 - Pro rata issue 11 Is security holder approval required? 12 Is the issue renounceable or nonrenounceable? 13 Ratio in which the +securities will be offered 14 +Class of +securities to which the offer relates 15 ⁺Record date to determine entitlements

16

17

entitlements?

to fractions

Will holdings on different registers (or subregisters) be aggregated for calculating

Policy for deciding entitlements in relation

⁺ See chapter 19 for defined terms.

18	Names of countries in which the entity has +security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

⁺ See chapter 19 for defined terms.

32		do security holders dispose of their ements (except by sale through a r)?
33	⁺ Issue	date
		Quotation of securities omplete this section if you are applying for quotation of securities
34	Type of tick of	of securities one)
(a)		⁺ Securities described in Part 1
(b)		All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entiti	ies th	at have ticked box 34(a)
Additi	onal s	ecurities forming a new class of securities
Tick to documen		e you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional *securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	14,052,810	
39	⁺ Class of ⁺ securities for which quotation is sought	Ordinary shares	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes	
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in clause 38)	Number 234,514,050	⁺ Class Ordinary shares

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

== == == == ==

Sign here:			
	(Director)		
Print name:	Graham Kelly		

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – issues exceeding 15% of capital

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

Insert number of fully paid ⁺ordinary 158,625,294 securities on issue 12 months before the +issue date or date of agreement to issue

Add the following:

- Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2
- Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval
- Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period

Note:

- Include only ordinary securities here other classes of equity securities cannot be added
- Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed
- It may be useful to set out issues of securities on different dates as separate line items

Subtract the number of fully paid ⁺ordinary - securities cancelled during that 12 month period

"A" 187,611,240

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"

"B" 0.15

[Note: this value cannot be changed]

Multiply "A" by 0.15 28,141,686

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of ⁺equity securities issued or agreed to be issued in that 12 month period *not counting* those issued:

- Under an exception in rule 7.2
- Under rule 7.1A
- With security holder approval under rule 7.1 and 7.4

Note:

- This applies to equity securities, unless specifically excluded not just ordinary securities
- Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed
- It may be useful to set out issues of securities on different dates as separate line items

"C" 28,141,686

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15 28,141,686

Note: number must be same as shown in Step 2

Subtract "C" 28,141,686

Note: number must be same as shown in Step 3

Total ["A" x 0.15] – "C" Nil

placement capacity under rule 7.1

[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

"A" 187,611,240

Note: number must be same as shown in Step 1 of Part 1

Step 2: Calculate 10% of "A"

"D" 0.10

Note: this value cannot be changed

Multiply "A" by 0.10 18,761,124

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used

Insert number of ⁺equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

Notes:

- This applies to equity securities not just ordinary securities
- Include here if applicable the securities the subject of the Appendix 3B to which this form is annexed
- Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained
- It may be useful to set out issues of securities on different dates as separate line items

E" 18,761,124

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10 18,761,124

Note: number must be same as shown in Step 2

Subtract "E" 18,761,124

Note: number must be same as shown in Step 3

Total ["A" x 0.10] – "E" Nil

Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.